ArticlePharmaceutical research2014
Long-acting atypical antipsychotics: characterization of the local tissue response.
Article in Pharmaceutical research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 40 citations in OpenAlex.
- Making the Case for Organ-on-Chip Platforms in Long-Acting Therapeutics Development.Advanced healthcare materials · 2026Review
- Clinical Consequences of Inadvertent Intramuscular Administration of Subcutaneous Risperidone Formulation.Case reports in psychiatry · 2026Article
- Mechanistic Modeling of Intramuscular Administration of a Long-acting Injectable Accounting for Tissue Response At the Depot Site.The AAPS journal · 2025Article
- Improving in vivo release prediction from in situ forming depots with a novel flow-through in vitro dissolution apparatus.International journal of pharmaceutics · 2025Article
- Leveraging Model Master Files for Long-Acting Injectables.Pharmaceutical research · 2025Article
- Design of Nanocrystalline Suspension of Dutasteride for Intramuscular Prolonged Delivery.Nanomaterials (Basel, Switzerland) · 2024Article
- Patient-Centric Long-Acting Injectable and Implantable Platforms─An Industrial Perspective.Molecular pharmaceutics · 2024Review
- Tricaprylin-based drug crystalline suspension for intramuscular long-acting delivery of entecavir with alleviated local inflammation.Bioengineering & translational medicine · 2024Article
- Development of Mechanistic In Vitro-In Vivo Extrapolation to Support Bioequivalence Assessment of Long-Acting Injectables.Pharmaceutics · 2024Article
- Role of Modeling and Simulation in Preclinical and Clinical Long-Acting Injectable Drug Development.The AAPS journal · 2023Review
- A Retrospective Analysis of Preclinical and Clinical Pharmacokinetics from Administration of Long-Acting Aqueous Suspensions.Pharmaceutical research · 2023Article
- Long-Acting Injectable Aqueous Suspensions-Summary From an AAPS Workshop.The AAPS journal · 2023Review
- Pharmacokinetics of Long-Acting Aqueous Nano-/Microsuspensions After Intramuscular Administration in Different Animal Species and Humans-a Review.The AAPS journal · 2022Review
- Effect of Dispersion Medium on Pharmacokinetic Profile of Rotigotine Crystalline Suspension following Subcutaneous Injection.Pharmaceutics · 2022Article
- Design of Montelukast Nanocrystalline Suspension for Parenteral Prolonged Delivery.International journal of nanomedicine · 2022Article
- Evaluation of Loco-Regional Skin Toxicity Induced by an In Situ Forming Depot after a Single Subcutaneous Injection at Different Volumes and Flow Rates in Göttingen Minipigs.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLong-acting injectables (LAIs) are increasingly recognized as an effective therapeutic approach for treating chronic conditions. Many LAIs are formulated to create a poorly soluble depot from which the active agent is delivered over time. This long residing depot can cause localized chronic-active inflammation in the tissue, which has not been well defined in the literature. The purpose of this work is to establish an experimental baseline for describing these responses.
methodsNon-human primates and rodents were used to examine the response to LAI formulations of two clinically relevant atypical antipsychotics, aripiprazole monohydrate and olanzapine pamoate monohydrate.
resultsA foreign body response develops with elevations of key cytokines such as IL-1α, IL-1β, TNFα, and IL6 at the site of injection. However, the tissue response for the two atypical antipsychotics compounds diverge as evidenced by quantitative differences observed in cytokine levels at various time points after dosing.
conclusionsOur studies show that, while the drugs are in the same therapeutic class, the response to each of these compounds can be distinguished qualitatively and quantitatively, supporting the idea that the injection site reaction involves a multiplicity of factors including the properties of the compound and cellular dynamics at the site of injection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.